胰腺癌是全世界公認的高度惡性疾病之一。由于胰腺癌疾病隱匿、病情發(fā)展較快，目前尚無明確有效的治療方案，基于吉西他濱的聯(lián)合化療仍是最主要的臨床手段。研究發(fā)現(xiàn)胰腺癌細胞對吉西他濱有高度化療耐藥性，因此治療效果并不理想，而且與細胞毒性藥物的聯(lián)用方案對患者有較強的機體損傷。深入研究發(fā)現(xiàn)與吉西他濱可聯(lián)用于治療胰腺癌，安全合理并能增加吉西他濱治療效果的增效劑成為領域重點問題。關注不同增效劑與吉西他濱聯(lián)合應用的作用機制，分析其應用效果，可為吉西他濱促胰腺癌細胞凋亡作用的發(fā)揮提供有利影響，有望為胰腺癌患者帶來福音。

Pancreatic cancer is recognized as one of the most highly malignant diseases in the world. Because of the stealthiness and rapid progression of pancreatic cancer, there is no effective treatment scheme. Combined chemotherapies based on gemcitabine are primary clinical methods. Researches found that pancreatic cancer cells had highly chemotherapy resistance to gemcitabine, and its effectiveness was far from the expected result. Moreover, the combination with cytotoxic drugs has strong injuries to patients. Therefore, researchers focus on seeking synergists which can be used with gemcitabine to enhance its pharmacological action in the treatment of pancreatic cancer. To study the mechanism of the combination of synergists and gemcitabine may provide it with positive impact on promoting cell apoptosis, which will bring benefit for pancreatic cancer patients.